Drug Type Small molecule drug |
Synonyms OPC-61815, Samtasu, サムタス |
Target |
Mechanism AVPR2 antagonists(Vasopressin V2 receptor antagonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Inactive Organization- |
Drug Highest PhaseApproved |
First Approval Date JP (28 Mar 2022), |
Regulation- |
Molecular FormulaC26H26ClN2NaO6P |
InChIKeyPWJANPIMBWGICU-UHFFFAOYSA-N |
CAS Registry942619-79-6 |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Body fluid retention | JP | 28 Mar 2022 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Heart Failure | NDA/BLA | CN | 15 Dec 2023 | |
Edema, Cardiac | NDA/BLA | CN | - |
Phase 1 | - | 8 | nntznogkfe(yliqbzxxht) = nziktirbvw usxmhxobpt (hrwxmrqvxs, rfkjihlchx - iaqqzbjvox) View more | - | 06 Oct 2021 | ||
Phase 3 | 45 | qdpkpvbsbb(frqayhnrsd) = xcupzxfdox mxqdhgcnpv (smfhhynamy, laellrlvzr - zrrvlqvppo) View more | - | 05 Sep 2021 | |||
Phase 3 | 294 | (OPC-61815 Injection 16 mg) | azgdulsiji(wtyxtyvmat) = jmezpedqes vhtlvevgml (xkfwueeeba, aslywbmvmr - axcaugadiv) View more | - | 05 Aug 2021 | ||
(Tolvaptan Tablet 15mg) | azgdulsiji(wtyxtyvmat) = iywlhoukjk vhtlvevgml (xkfwueeeba, hlsefodfdl - jwhhkyjaqx) View more | ||||||
Not Applicable | 61 | (OPC-61815 Injection 2mg) | oqgzjsbvvi(kbxtvladkq) = bksdbuynrz xcbjkblfks (dogrnnbamd, kqljfpihjr - gqbazquwlf) View more | - | 28 Jul 2021 | ||
(OPC-61815 Injection 4mg) | oqgzjsbvvi(kbxtvladkq) = yyxawbxemf xcbjkblfks (dogrnnbamd, kstfzmwqfc - wgaxfycfxn) View more |